{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:10:09Z","timestamp":1768288209414,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jpba.2018.01.038","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T17:21:32Z","timestamp":1517419292000},"page":"155-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations"],"prefix":"10.1016","volume":"152","author":[{"given":"Mohammad Nabil","family":"Abo-Zeid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha N.","family":"Atia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia M.","family":"El-Gizawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa R.","family":"El-Shaboury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.01.038_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"G\u00f6tte","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2018.01.038_bib0010","first-page":"154","article-title":"Direct-acting antiviral medications for chronic hepatitis C virus infection","volume":"7","author":"Jazwinski","year":"2011","journal-title":"Gastroenterol. Hepatol. (N.Y.)"},{"key":"10.1016\/j.jpba.2018.01.038_bib0015","series-title":"The Encyclopedia of Hepatitis and Other Liver Diseases","author":"Chow","year":"2006"},{"key":"10.1016\/j.jpba.2018.01.038_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2040622310384308","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C virus infection","volume":"2","author":"Palumbo","year":"2011","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.jpba.2018.01.038_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.jpba.2018.01.038_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jpba.2018.01.038_bib0035","series-title":"Harvoni (Ledipasvir and Sofosbuvir) Tablets Prescribing Information","author":"Sciences","year":"2017"},{"key":"10.1016\/j.jpba.2018.01.038_bib0040","unstructured":"B.-M.S. Company, DAKLINZA\u2122 (daclatasvir) tablets prescribing information, Princeton, NJ 08543, USA, 2017. https:\/\/packageinserts.bms.com\/pi\/pi_daklinza.pdf."},{"key":"10.1016\/j.jpba.2018.01.038_bib0045","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5740\/jaoacint.16-0021","article-title":"A rapid and optimized LC\u2013MS\/MS method for the simultaneous extraction and determination of sofosbuvir and ledipasvir in human plasma","volume":"99","author":"Elkady","year":"2016","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.jpba.2018.01.038_bib0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC\u2013MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.01.038_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC\u2013MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.01.038_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC\u2013MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.01.038_bib0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC\u2013MS\/MS method for the quantification of direct antiviral dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.01.038_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2016.06.004","article-title":"Quantification of sofosbuvir and ledipasvir in human plasma by UPLC\u2013MS\/MS method: application to fasting and fed bioequivalence studies","volume":"1028","author":"Rezk","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.01.038_bib0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.saa.2017.08.023","article-title":"Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir","volume":"190","author":"Salama","year":"2018","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2018.01.038_bib0080","unstructured":"International Conference on Harmonization, Topic Q2 (R1) Validation of Analytical Procedures: Text and Methodology, 2005. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf."},{"key":"10.1016\/j.jpba.2018.01.038_bib0085","unstructured":"Food and Drug Administration, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations, 2003."},{"key":"10.1016\/j.jpba.2018.01.038_bib0090","unstructured":"Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 2001. http:\/\/www.labcompliance.de\/documents\/FDA\/FDA-Others\/Laboratory\/f-507-bioanalytical-4252fnl.pdf."},{"key":"10.1016\/j.jpba.2018.01.038_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2018.01.038_bib0100","series-title":"Colorimetric and Fluorimetric Analysis of Organic Compounds and Drugs","author":"Pesez","year":"1974"},{"key":"10.1016\/j.jpba.2018.01.038_bib0105","series-title":"Fundamentals of Analytical Chemistry","author":"Skoog","year":"2014"},{"key":"10.1016\/j.jpba.2018.01.038_bib0110","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1021\/j100041a006","article-title":"Solvent relaxation around the excited-state of indole\u2014analysis of fluorescence lifetime distributions and time-dependence spectral shifts","volume":"99","author":"Vincent","year":"1995","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.jpba.2018.01.038_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir A NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jpba.2018.01.038_bib0120","series-title":"Introduction to Pharmaceutical Chemical Analysis","author":"Hansen","year":"2012"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851732650X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851732650X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T14:54:09Z","timestamp":1535122449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851732650X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"alternative-id":["S073170851732650X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.01.038","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}